# US 10,118,014 B2 · Device and methods for targeted tissue drug delivery > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,118,014 B2 - Document ID: US10118014B2 - Status: Granted - Kind: B2 - Application number: 14/427,607 - Filed: 2013-09-09 - Published: 2015-08-13 - Granted: 2018-11-06 - Earliest claimed: 2012-09-11 - Assignees: Native Cardio, Inc. - Applicants: Native Cardiovascular LLC - Inventors: Young D. Kim; Joseph V. Pergolizzi; Scot Johnson - Web page: https://patentgrep.com/patent/US10118014B2 ## CPC - A61M 25/0023: {by the form of the lumen, e.g. cross-section, variable diameter} - A61N 1/0587: {Epicardial electrode systems; Endocardial electrodes piercing the pericardium} - A61N 1/0597: {Surface area electrodes, e.g. cardiac harness} - A61M 19/00: Local anaesthesia (syringes therefor A61M5/00); Hypothermia (A61M5/42 takes precedence; cooling blood in a bypass of the arterial system A61M1/36) - A61M 2025/0004: {having two or more concentrically arranged tubes for forming a concentric catheter system} - A61N 1/046: {Specially adapted for shock therapy, e.g. defibrillation} - A61N 1/0476: {Array electrodes (including any electrode arrangement with more than one electrode for at least one of the polarities)} - A61N 1/0595: {Temporary leads} - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) ## Abstract Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs. ## Claims ### Claim 1 A minimally invasive device for treatment of a patient, the device comprising: a. at least one inner catheter comprising at least one drug delivery channel located within the inner catheter, the at least one drug delivery channel adapted to deliver a drug to a cardiac surface of the patient; b. an outer catheter substantially surrounding the at least one inner catheter; c. a plurality of electrically conductive elements within the inner catheter and surrounding the drug delivery channel and extending to be also located at a substantially distal portion of the device; and d. at least one membrane interconnecting the plurality of electrically conductive elements at the substantially distal portion of the device, wherein the membrane is adapted to deform with the beating of the heart, wherein the plurality of electrically conductive elements interconnecting with the membrane at the substantially distal portion of the device are arranged in a flower-like arrangement fanning out from a central hub, wherein the plurality of electrically conductive elements are adapted to provide defibrillation energy to a cardiac surface of the patient, wherein the device is effective for treating chronic atrial fibrillation. ### Claim 2 (depends on 1) The device according to claim 1, wherein at least one adhesive material is provided on an underside of the membrane. ### Claim 3 (depends on 2) The device according to claim 2, wherein the at least one adhesive material comprises at least one adhesive polymer. ### Claim 4 (depends on 1) The device according to claim 1, comprising at least one anti-arrhythmic drug. ### Claim 5 (depends on 4) The device according to claim 4, wherein the at least one anti-arrhythmic drug is selected from the group consisting of procainamide, amiodarone, a combination of procainamide and at least one other anti-arrhythmic drug, a combination of amiodarone and at least one other anti-arrhythmic drug, and a combination of procainamide, amiodarone and at least one other anti-arrhythmic drug. ### Claim 6 (depends on 1) The device according to claim 1, comprising at least one anesthetic drug. ### Claim 7 (depends on 6) The device according to claim 6, wherein the anesthetic drug is selected from the group consisting of procaine, lidocaine, a combination of procaine and at least one other anesthetic drug, a combination of lidocaine an at least one other anesthetic drug, and a combination of procaine, lidocaine, and at least one other anesthetic drug. ### Claim 8 A method of treating a patient suffering from an abnormal cardiac rhythm, the method comprising: implanting a minimally invasive device in a patient in need of treatment for chronic atrial fibrillation, the device comprising: a. at least one inner catheter comprising at least one drug delivery channel located within the inner catheter, the at least one drug delivery channel delivering a drug to a cardiac surface of the patient; b. an outer catheter substantially surrounding the at least one inner catheter; c. a plurality of electrically conductive elements within the inner catheter and surrounding the drug delivery channel and extending to be also located at a substantially distal portion of the device; and d. at least one membrane interconnecting the plurality of electrically conductive elements at the substantially distal portion of the device, wherein the membrane is adapted to deform with the beating of the heart, wherein the plurality of electrically conductive elements interconnecting with the membrane at the substantially distal portion of the device are arranged in a flower-like arrangement fanning out from a central hub, wherein the plurality of electrically conductive elements provide defibrillation energy to a cardiac surface of the patient, wherein the distal portion of the device further comprises at least one drug release site for delivery of at least one drug to the cardiac surface of the patients, wherein the method is effective for treating chronic atrial fibrillation. ### Claim 9 (depends on 8) The method according to claim 8, wherein at least one adhesive material is provided on an underside of the membrane. ### Claim 10 (depends on 9) The method according to claim 9, wherein the at least one adhesive material comprises at least one adhesive polymer. ### Claim 11 (depends on 8) The method according to claim 8, further comprising delivering at least one anti-arrhythmic drug through the device. ### Claim 12 (depends on 11) The method according to claim 11, wherein the at least one antiarrhythmic drug is selected from the group consisting of procainamide, amiodarone, a combination of procainamide and at least one other anti-arrhythmic drug, a combination of amiodarone and at least one other anti-arrhythmic drug, and a combination of procainamide, amiodarone and at least one other anti-arrhythmic drug. ### Claim 13 (depends on 8) The method according to claim 8, further comprising delivering at least one anesthetic drug through the device. ### Claim 14 (depends on 13) The method according to claim 13, wherein the anesthetic drug is selected from the group consisting of procaine, lidocaine, a combination of procaine and at least one other anesthetic drug, a combination of lidocaine and at least one other anesthetic drug, and a combination of procaine, lidocaine, and at least one other anesthetic drug. ### Claim 15 (depends on 8) The method according to claim 8, wherein the patient is treated for ventricular fibrillation.